# Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

> **NCT07236099** · PHASE2 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 135 (estimated)

## Conditions studied

- Prurigo Nodularis (PN)

## Interventions

- **DRUG:** ICP-322
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07236099
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2027-03
- **Final completion:** 2027-10
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07236099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07236099, "Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07236099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*